Quality of Life Research

, Volume 7, Issue 1, pp 39-55

First online:

A questionnaire to assess the generic and disease-specific health outcomes of patients with chronic hepatitis C

  • Martha S. BaylissAffiliated withThe Health Institute, New England Medical Center
  • , Barbara GandekAffiliated withThe Health Institute, New England Medical Center
  • , Kathleen M. BungayAffiliated withThe Health Institute, New England Medical Center
  • , David SuganoAffiliated withUSA Schering-Plough Inc Pfizer Inc.
  • , Ming-Ann HsuAffiliated withThe Health Institute, New England Medical Center
  • , John E. WareJrAffiliated withTufts University School of Medicine USA and Harvard School of Public Health

Rent the article at a discount

Rent now

* Final gross prices may vary according to local VAT.

Get Access


A 69-item questionnaire measuring generic functioning and well-being and disease-specific health outcomes was developed and tested using the pre-treatment data from patients with chronic hepatitis C (CHC) participating in two randomized trials of interferon α-2b (n = 157). The questionnaire included all eight scales from the SF-36 and measures of nine other generic and disease-specific health concepts. Psychometric tests confirmed the assumptions underlying the construction and scoring of all generic and disease-specific scales. Cross-sectional tests of ‘known groups’ validity showed that CHC patients scored worse on the generic scales than patients with other chronic conditions and worse than a healthy general population. The generic and disease-specific scale scores were lower in the presence of physical findings of CHC, as hypothesized, but only the physical functioning and bodily pain scales were linked to cirrhosis or extreme alanine aminotransferase (ALT) ratios. This instrument will be useful in studies of health outcome among patients with CHC, a condition whose health burden appears to have been underestimated in studies to date.

Health status SF-36 Health Survey hepatitis C questionnaire